Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.2% Higher – Should You Buy?

Shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shot up 4.2% during trading on Monday . The stock traded as high as $0.49 and last traded at $0.47. 74,451 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 63,626 shares. The stock had previously closed at $0.45.

Hepion Pharmaceuticals Stock Performance

The business’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.68. The company has a market capitalization of $3.26 million, a P/E ratio of -0.11 and a beta of 1.70.

Institutional Trading of Hepion Pharmaceuticals

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC grew its stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 516,000 shares of the company’s stock after purchasing an additional 126,000 shares during the period. Armistice Capital LLC owned approximately 9.43% of Hepion Pharmaceuticals worth $526,000 at the end of the most recent reporting period. 17.24% of the stock is owned by institutional investors.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.